Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Blood 2007 Jun 13;109(11):4635-40. Epub 2007 Feb 13.

Department of Medical and Molecular Genetics, Guy's Hospital, King's College London, UK.

The FIP1L1-PDGFRA fusion gene is a recurrent molecular lesion in eosinophilia-associated myeloproliferative disorders, predicting a favorable response to imatinib mesylate. To investigate its prevalence, 376 patients with persistent unexplained hypereosinophilia were screened by the United Kingdom reference laboratory, revealing 40 positive cases (11%). To determine response kinetics following imatinib, real-time quantitative-polymerase chain reaction (RQ-PCR) assays were developed and evaluated in samples accrued from across the European LeukemiaNet. The FIP1L1-PDGFRA fusion transcript was detected at a sensitivity of 1 in 10(5) in serial dilution of the EOL-1 cell line. Normalized FIP1L1-PDGFRA transcript levels in patient samples prior to imatinib varied by almost 3 logs. Serial monitoring was undertaken in patients with a high level of FIP1L1-PDGFRA expression prior to initiation of imatinib (100 mg/d-400 mg/d). Overall, 11 of 11 evaluable patients achieved at least a 3-log reduction in FIP1L1-PDGFRA fusion transcripts relative to the pretreatment level within 12 months, with achievement of molecular remission in 9 of 11 (assay sensitivities 1 in 10(3)-10(5)). In 2 patients, withdrawal of imatinib was followed by a rapid rise in FIP1L1-PDGFRA transcript levels. Overall, these data are consistent with the exquisite sensitivity of the FIP1L1-PDGFRalpha fusion to imatinib, as compared with BCR-ABL, and underline the importance of RQ-PCR monitoring to guide management using molecularly targeted therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2006-10-050054DOI Listing
June 2007
18 Reads

Publication Analysis

Top Keywords

fip1l1-pdgfra fusion
12
imatinib mesylate
8
transcript levels
8
molecular remission
8
fip1l1-pdgfra transcript
8
fip1l1-pdgfra
6
imatinib
6
imatinib varied
4
prior imatinib
4
patient samples
4
levels patient
4
varied logs
4
samples prior
4
serial monitoring
4
level fip1l1-pdgfra
4
fip1l1-pdgfra expression
4
expression prior
4
prior initiation
4
high level
4
patients high
4

References

(Supplied by CrossRef)
A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.
Bacher et al.
Haematologica 2006
The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza et al.
Haematologica 2005

Similar Publications